ホーム > 小原 直/ Obara, Naoshi

小原 直

Obara, Naoshi

血液内科 , 教授
Faculty of Medicine

  1. 1. Tumor necrosis factor from leukemic environment stimulates hematopoietic stem/progenitor cells toward megakaryocyte/myeloid lineage bias. Hidekazu Nishikii; Riko Kikuchi; Takaharu Kimura; Mizuki Saito (+8 著者) Shigeru Chiba
      Experimental hematology 155: 105332 (2025) Semantic Scholar
  2. 2. Evaluation of Delayed Initiation of Lenalidomide Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Koji Kawamura; Nobuhiro Tsukada; Shun-Ichi Kimura; Shinichi Kako (+8 著者) Yoshinobu Kanda
      Hematological oncology 43: e70129 (2025) Semantic Scholar
  3. 3. Treatment burden in patients with paroxysmal nocturnal hemoglobinuria: an in-depth interview survey. Yasutaka Ueda; Naoshi Obara; Shikiko Ueno; Masatoshi Sakurai (+12 著者) Jun-Ichi Nishimura
      Annals of hematology 104: 3575 (2025) Semantic Scholar
  4. 4. Real-World Data on the p.Gly17Val RHOA Mutation in Diagnosing T Follicular Helper Cell Lymphomas. Yuri Tsuboi; Keiichiro Hattori; Naoki Kurita; Yasuhito Suehara (+11 著者) Mamiko Sakata-Yanagimoto
      Cancer medicine 14: e70955 (2025) Semantic Scholar
  5. 5. A Case of Multiple Myeloma in a Patient with Birt-Hogg-Dube Syndrome. Fumiaki Matsumura; Tatsuhiro Sakamoto; Hirayasu Kai; Toshiaki Usui (+15 著者) Mamiko Sakata-Yanagimoto
      Internal medicine (Tokyo, Japan) 64: 2764 (2025) Semantic Scholar
  6. 6. Eltrombopag-Induced Falsely Elevated Bilirubin Concentrations in Enzymatic and Vanadate Oxidation Assays: Involvement of High Serum Eltrombopag Concentrations. Shun Oda; Kosuke Doki; Naoshi Obara; Yoshiharu Suzuki (+1 著者) Masato Homma
      Therapeutic drug monitoring 47: 635 (2025) Semantic Scholar
  7. 7. Case report: Spontaneous remission of severe aplastic anemia mediated by mutant hematopoietic stem cells evading T-cell attack. Kohei Shiroshita; Yoshitaka Zaimoku; Himari Kudo; Naoshi Obara (+6 著者) Shinji Nakao
      Frontiers in immunology 16: 1635943 (2025) Semantic Scholar
  8. 8. Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings. Naoshi Obara; Shigeki Hatanaka; Yukie Tsuji; Koji Higashi
      International journal of hematology 120: 665 (2024) Semantic Scholar
  9. 9. Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment. Zenjiro Sampei; Kenta Haraya; Siok Wan Gan; Masaru Muraoka (+6 著者) Yasutaka Ueda
      International journal of molecular sciences 25: (2024) Semantic Scholar
  10. 10. 血液悪性腫瘍患者における精子凍結保存の現状 単一施設での検討 本多 伸一郎; 栗田 尚樹; 古城 公佑; 池見 亜也子 (+9 著者) 坂田 麻実子
      日本血液学会学術集会 86回: O3 (2024)
  11. 11. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition. Alexander Röth; Guangsheng He; Hongyan Tong; Zenghua Lin (+23 著者) Bing Han
      American journal of hematology 99: 1768 (2024) Semantic Scholar
  12. 12. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia. Koji Izutsu; Hisashi Kato; Naohiro Sekiguchi; Tomoaki Fujisaki (+6 著者) Ei Fujikawa
      International journal of hematology 120: 80 (2024) Semantic Scholar
  13. 13. Impact of CD34 positive cell dose in donor graft on the outcomes after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide - A retrospective single-center study with a Japanese cohort. Yumiko Maruyama; Hidekazu Nishikii; Naoki Kurita; Tatsuhiro Sakamoto (+6 著者) Shigeru Chiba
      Blood cells, molecules & diseases 105: 102820 (2024) Semantic Scholar
  14. 14. Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors. Naoshi Obara; Kensuke Usuki; Takeshi Hayashi; Masato FujiiTakayuki Ikezoe
      International journal of hematology 119: 255 (2024) Semantic Scholar
  15. 15. [Successful BTK inhibitor therapy for refractory transformed B-cell lymphoma originating from an MYD88 mutant clone]. Atsushi Uehara; Hidekazu Nishikii; Yasuhito Suehara; Ryota Matsuoka (+11 著者) Shigeru Chiba
      [Rinsho ketsueki] The Japanese journal of clinical hematology 65: 1368 (2024) Semantic Scholar
  16. 16. [Current trends in the treatment of aplastic anemia]. Naoshi Obara
      [Rinsho ketsueki] The Japanese journal of clinical hematology 65: 514 (2024) Semantic Scholar
  17. 17. Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine. Shinichi Ogawa; Tatsuhiro Sakamoto; Ryota Matsuoka; Kantaro Ishitsuka (+14 著者) Shigeru Chiba
      Cancer reports (Hoboken, N.J.) 7: e1938 (2024) Semantic Scholar
  18. 18. [Durable remission of T-cell prolymphocytic leukemia with CLEC16A::IL2 after allogeneic hematopoietic stem cell transplantation]. Haruka Momose; Naoki Kurita; Hidekazu Nishikii; Nozomi Yusa (+11 著者) Shigeru Chiba
      [Rinsho ketsueki] The Japanese journal of clinical hematology 65: 35 (2024) Semantic Scholar
  19. 19. A longitudinal analysis of paroxysmal nocturnal haemoglobinuria-type cells in patients with bone marrow failure: Results of a prospective multi-centre study in Japan. Ken Ishiyama; Yuji Yonemura; Tatsuya Kawaguchi; Kohei Hosokawa (+12 著者) Shinji Nakao
      British journal of haematology 203: 468 (2023) Semantic Scholar
  20. 20. Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia. Tatsuhiro Sakamoto; Naoshi Obara; Yumiko Maruyama; Takayasu Kato (+7 著者) Shigeru Chiba
      European journal of haematology 111: 768 (2023) Semantic Scholar
1 2 3 … 8

書籍等出版物情報はまだありません。

講演・口頭発表情報はまだありません。

 243 total views